DSpace Repository

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

Show simple item record

dc.contributor Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Di Yacovo, María Silvana
dc.contributor.author Moltó, José
dc.contributor.author Ferrer, Elena
dc.contributor.author Curran, Adrian
dc.contributor.author Else, Laura
dc.contributor.author Gisslén, Magnus
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Tiraboschi, Juan M.
dc.contributor.author Niubò, Jordi
dc.contributor.author Vila, Antonia
dc.contributor.author Zetterberg, H.
dc.contributor.author Back, David
dc.contributor.author Podzamczer Palter, Daniel
dc.date.accessioned 2015-06-08T10:25:42Z
dc.date.available 2015-06-08T10:25:42Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., et al. (2015). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy, 70(5), 1513-1516. ca_ES
dc.identifier.issn 1460-2091
dc.identifier.uri http://hdl.handle.net/10854/4063
dc.description.abstract Objectives: The objective of this study was to assess whether a lower dose than the currently used one of darunavir/ ritonavir might achieve good CSF concentrations and contribute to inhibition of CNS viral replication. Patients and methods: This was a substudy of a randomized, open, multicentre study (eudraCT 2011-006272- 39), comparing the efficacy and safety of 800/100 mg of darunavir/ritonavir (darunavir 800) versus 600/100 mg of darunavir/ritonavir (darunavir 600) once daily plus tenofovir/emtricitabine or abacavir/lamivudine in 100 virologically suppressed patients. Paired blood and CSF samples were obtained. Total plasma darunavir concentrations were determined by HPLC, and CSF concentrations by liquid chromatography–tandem MS. Viral load (VL) was determined in plasma and CSF (limit of detection¼40 copies/mL) by PCR. Results: Sixteen patients were enrolled. The median (range) of darunavir CSF concentrations in darunavir 600 (n¼8) and darunavir 800 (n¼8) patients was 17.08 (5.79–30.19) and 13.23 (3.47–32.98) ng/mL, respectively (P¼0.916). The median (range) darunavir CSF:plasma ratio was 0.010 (0.005–0.022) in darunavir 600 patients and 0.008 (0.004–0.017) in the darunavir 800 arm (P¼0.370). All 16 patients had a VL,40 copies/mL in plasma and 14 had a VL,40 copies/mL in CSF. Of the two patients with detectable CSF VL (280 copies/mL and 159 copies/mL), one was receiving darunavir 600 and the other darunavir 800 plus tenofovir/emtricitabine. Of note, these patients had the lowest CSF darunavir concentrations in their respective groups: 5.79 ng/mL (802 ng/mL in plasma) and 3.47 ng/mL (958 ng/mL in plasma). Conclusions: Darunavir CSF and plasma concentrations were comparable between the two arms. However, one patient from each group (with the lowest CSF darunavir concentrations in their respective groups) had detectable CSF VL despite undetectable plasma VL. ca_ES
dc.format application/pdf
dc.format.extent 4 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Oxford University Press ca_ES
dc.rights Tots els drets reservats ca_ES
dc.rights (c) Oxford University Press
dc.subject.other Sida -- Tractament ca_ES
dc.subject.other VIH (Virus) ca_ES
dc.title Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1093/jac/dku558
dc.rights.accesRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES
dc.indexacio Indexat a WOS/JCR

Files in this item

Show simple item record

Search RIUVic


Browse

Statistics